Transform Your Journey with Mounjaro®.
A medically supervised weight management programme using tirzepatide - the breakthrough dual-action GLP-1 and GIP receptor agonist clinically shown to reduce body weight by up to 22%.
MHRA Approved
Mounjaro® is approved by the MHRA for chronic weight management in adults.
Your Weight Loss Pathway
Our clinical process is designed to ensure you receive safe, effective care with ongoing professional support every step of the way.
01. Online Consultation
Complete a health assessment covering your medical history, current weight, lifestyle, and weight loss goals. A mandatory safety step before any prescription.
02. Clinical Review
A UK-registered prescriber reviews your assessment to confirm Mounjaro® is clinically appropriate and safe for your circumstances, including BMI and health markers.
03. Discreet Delivery
Your medication is dispensed from our GPhC pharmacy and shipped in plain, unbranded packaging to your door, on a 4-week supply cycle.
Why Mounjaro®?
Tirzepatide (Mounjaro®) is the first and only dual-action GIP and GLP-1 receptor agonist. Unlike single-action treatments, it targets two hunger hormones simultaneously - delivering significantly greater weight loss results in clinical trials.
- Dual-Action MechanismActivates both GIP and GLP-1 receptors to suppress appetite and improve metabolic function.
- Clinically Superior ResultsSURMOUNT trials showed up to 22.5% average body weight reduction over 72 weeks.
- MHRA & NICE ApprovedLicensed in the UK for chronic weight management in adults with a qualifying BMI.
“The clinical evidence for tirzepatide is exceptional. For appropriate patients, Mounjaro® represents one of the most effective pharmacological tools we have for sustainable weight management.”
Safety & Information
Patient Confidentiality
Your programme is entirely private. All consultations are end-to-end encrypted, and your medication is shipped in plain unbranded packaging with no pharmacy markings on the exterior. We never share your data with third parties without your explicit consent.
How is Mounjaro® administered?
Mounjaro® is a once-weekly subcutaneous injection using a pre-filled auto-injector pen. Starting dose is 2.5mg, titrated gradually up to a maximum of 15mg based on your clinical response and tolerance.
Side Effects
Most common are gastrointestinal - nausea, reduced appetite, and mild diarrhoea - particularly in the early weeks. These typically reduce as your body adjusts to the medication.
24/7 Clinical Support Messaging
Your transformation starts today.
Join thousands of patients achieving sustainable, clinically supported weight loss through our professional programme.